Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Maryia Zhdanava,Timothy Fitzgerald,Dominic Pilon,Rachel E. Teneralli,Aditi Shah,Lilian Diaz,Patrick Lefebvre,Steven R. Feldman
DOI: https://doi.org/10.1080/09546634.2024.2349658
2024-05-17
Journal of Dermatological Treatment
Abstract:Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.
dermatology
What problem does this paper attempt to address?